Woodruff et al. Health care resource use of paliperidone palmitate 3-month injection versus placebo: an analysis of the PSY-3012 Phase 3 clinical trial hospital data.

TITUSVILLE, N.J., Sept. 1, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug A ...

Results of the study served as the basis for the recent New Drug Application (NDA) filing for three-month paliperidone palmitate injection to treat schizophrenia in adults with the U.S. Food and ...

The priority review was given based on phase 3 data that evaluated the efficacy of the 3-month treatment vs. placebo. The study was stopped early for positive outcomes, according to the press release.

Every-6-month dosing of the long-acting injectable paliperidone palmitate (Invega Hafyera) for schizophrenia was effective and safe up to 3 years, researchers reported during a poster presentation ...

The US Food and Drug Administration (FDA) has approved a 6-month injection form of the long-acting atypical antipsychotic paliperidone palmitate (Invega Hafyera, Janssen Pharmaceuticals) for the ...

Janssen R&D announced that results from a Phase 3 clinical study with three-month paliperidone palmitate have been published in JAMA Psychiatry. This international, randomized, multicenter, double ...

Before transitioning to INVEGA HAFYERA, patients must be adequately treated with INVEGA SUSTENNA (1-month paliperidone palmitate) for at least four months, or INVEGA TRINZA (3-month paliperidone ...

Janssen R&D announced that it has submitted a New Drug Application (NDA) to the FDA, for three-month paliperidone palmitate as treatment for schizophrenia in adults. The NDA submission is based on ...

Please provide your email address to receive an email when new articles are posted on . Paliperidone 3-month LAI, aripiprazole LAI, olanzapine LAI and clozapine fared similarly to commonly used ...

The FINANCIAL — A study published in The Journal of Clinical Psychiatry shows that long-acting INVEGA SUSTENNA (paliperidone palmitate) was effective six months longer than commonly prescribed ...

The FINANCIAL -- Three-month paliperidone palmitate, an investigational atypical antipsychotic, significantly delayed time to relapse compared to placebo in patients with schizophrenia, according ...